Oxford University Press

SHERPA: Yellow

People

  1. Drilon
    Drilon
  2. Motzer
    Motzer
  3. Mellinghoff
    Mellinghoff
  4. Shuman
    Shuman
  5. Rosenblum
    Rosenblum
  6. Dunkel
    Dunkel
  7. Karajannis
    Karajannis
  8. Saltz
    Saltz
  9. Souweidane
    Souweidane
  10. Panageas
    Panageas

Groups

  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)
  7. Department of Pathology and Laboratory Medicine (415)
  8. Gastrointestinal Oncology Service (386)
  9. Genitourinary Oncology Service (367)
  10. Tow Center for Developmental Oncology (TCDO) (352)
Search Within
Formats
  1. Journal Article (2131)
  2. Meeting Abstract (2072)
  3. Book Section (192)
  4. Review (92)
  5. Editorial (84)
  6. Guidelines (36)
  7. Correspondence (26)
  8. Book Whole (18)
  9. Conference Paper (15)
  10. Research Letter (10)
Groups
  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)

More Groups

People
  1. Lisa De Angelis (119)
  2. Alexander Drilon (108)
  3. Robert Motzer (96)
  4. Ingo Mellinghoff (93)
  5. Stewart Shuman (88)
  6. Marc Rosenblum (87)

More People

Years
  1. 2025 (129)
  2. 2024 (304)
  3. 2023 (320)
  4. 2022 (331)
  5. 2021 (323)
  6. 2020 (325)

More Years

Publications
  1. Annals of Oncology (1670)
  2. Neuro-Oncology (855)
  3. JNCI: Journal of the National Cancer Institute (492)
  4. Nucleic Acids Research (210)
  5. Clinical Infectious Diseases (140)
  6. American Journal of Clinical Pathology (106)

More Publications

Results (4676)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase Ib KEYNOTE-200: A study of an intravenously delivered oncolytic virus, coxsackievirus A21 in combination with pembrolizumab in advanced NSCLC and bladder cancer patients
    Meeting Abstract

    Rudin, C. M.; Pandha, H. S.; Gupta, S.; Zibelman, M. R.; Akerley, W.; Day, D.; Hill, A. G.; Sanborn, R. E.; O'Day, S. J.; Clay, T. D.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • A phase I/II study of chemo-immunotherapy with durvalumab (durva) and pegylated liposomal doxorubicin (PLD) in platinum-resistant recurrent ovarian cancer (PROC)
    Meeting Abstract

    O'Cearbhaill, R. E.; Wolfer, A.; Disilvestro, P.; O'Malley, D. M.; Sabbatini, P.; Shohara, L.; Schwarzenberger, P. O.; Ricciardi, T.; Macri, M.; Ryan, A.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • EV-301: An open-label, randomized phase III study to evaluate enfortumab vedotin versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial cancer (la/mUC)
    Meeting Abstract

    Petrylak, D. P.; Rosenberg, J.; Duran, I.; Loriot, Y.; Sonpavde, G.; Wu, C.; Gartner, E.; Melhem-Bertrandt, A.; Powles, T.
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Phase I study of the AXL inhibitor DS-1205c in combination with osimertinib in subjects with metastatic or unresectable EGFR-mutant NSCLC
    Meeting Abstract

    Planchard, D.; Janne, P. A.; Yu, H. A.; Moro-Sibilot, D.; Goldberg, T.; Gu, X.; Li, J.; McGill, J.; Yu, C.; Slosberg, E.
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Tumour growth rate (TGR) when using lanreotide Autogel® (LAN) before, during and after peptide receptor radionuclide therapy (PRRT) in advanced neuroendocrine tumours (NETs)
    Meeting Abstract

    Prasad, V.; Srirajaskanthan, R.; Grana, C. M.; Baldari, S.; Shah, T.; Lamarca, A.; Courbon, F.; Scheidhauer, K.; Baudin, E.; Truong-Thanh, X. M.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • PD-L1 expression and T-cell inflamed gene expression profile (GEP) in Korean and US patients (pts) with advanced gastric cancer (GC)
    Meeting Abstract

    Rha, S. Y.; Ku, G. Y.; Kim, H. S.; Chung, H. C.; Amlashi, F. G.; Maru, D. M.; Fein, C.; Tang, L.; Savage, M. J.; Zhou, W.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Subgroup analysis of rucaparib in platinum-sensitive recurrent ovarian carcinoma: Effect of prior chemotherapy regimens in ARIEL3
    Meeting Abstract

    Lorusso, D.; Coleman, R. L.; Oza, A. M.; Aghajanian, C.; Oaknin, A.; Dean, A.; Colombo, N.; Weberpals, J. I.; Clamp, A. R.; Scambia, G.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Prospective validation of prognostic scores to improve patient selection for immuno-oncology trials
    Meeting Abstract

    Massard, C.; Segal, N. H.; Cho, D. C.; Papadimitrakopoulou, V. A.; Rizvi, N. A.; Cho, B. C.; Yu, L.; Yang, H.; Hsieh, H. J.; Zhang, J.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • CTC-based biomarkers & PSMA-targeted imaging in patients with metastatic castrate-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Morris, M. J.; Vogelzang, N. J.; Sartor, O.; Armour, A.; Messmann, R.; Groaning, M.; Robarts, A.; Tolcher, A. W.; Gordon, M.; Babiker, H. M.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Responses and durability of clinical benefit in triple negative breast cancer patients treated with pegilodecakin monotherapy or in combination with platinum plus taxane-based chemotherapy
    Meeting Abstract

    Naing, A.; Autio, K. A.; Falchook, G. S.; Meric-Bernstam, F.; Litton, J. K.; Ibrahim, N. K.; Hung, A.; Oft, M.; Leveque, J.; Patel, M. R.
    Annals of Oncology (2018)

    Fulltext@MSK | Save